Boston Scientific Co. (NYSE:BSX – Get Free Report) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 12,200,000 shares, an increase of 10.7% from the August 31st total of 11,020,000 shares. Based on an average daily trading volume, of 5,530,000 shares, the days-to-cover ratio is currently 2.2 days.
Insider Activity
In other news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the sale, the executive vice president now owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.50% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in BSX. Eagle Bay Advisors LLC lifted its position in shares of Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 309 shares in the last quarter. First Foundation Advisors acquired a new stake in Boston Scientific during the 1st quarter valued at $25,000. Triad Wealth Partners LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at $26,000. Andra AP fonden acquired a new stake in shares of Boston Scientific in the second quarter worth $29,000. Finally, RiverPark Advisors LLC purchased a new position in shares of Boston Scientific during the first quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on BSX
Boston Scientific Price Performance
Shares of BSX traded up $0.34 during mid-day trading on Tuesday, hitting $84.14. The company’s stock had a trading volume of 4,354,164 shares, compared to its average volume of 6,002,487. Boston Scientific has a fifty-two week low of $48.35 and a fifty-two week high of $84.89. The stock has a market capitalization of $123.44 billion, a price-to-earnings ratio of 70.71, a PEG ratio of 2.78 and a beta of 0.79. The firm has a 50-day moving average price of $79.55 and a 200 day moving average price of $75.56. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The company had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. During the same period in the previous year, the firm earned $0.53 earnings per share. Boston Scientific’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, research analysts predict that Boston Scientific will post 2.4 EPS for the current fiscal year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Featured Articles
- Five stocks we like better than Boston Scientific
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Lennar Stock Could Be the Best Play in the Housing Market
- EV Stocks and How to Profit from Them
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What Are Growth Stocks and Investing in Them
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.